Income Taxes	9 Months Ended
Jun. 30, 2013
Income Taxes
Income Taxes	3. Income Taxes At the end of each interim reporting period, the Company prepares an estimate of the annual effective income tax rate, which is applied to year-to-date income to compute income tax expense exclusive of discrete items. Tax items discrete to a specific quarter are included in computing the income tax expense for that quarter. The estimated annual effective tax rate used in providing for income taxes on a year-to-date basis may change in subsequent interim periods. The income tax (benefit) expense for the three and nine months ended June 30, 2013 was ($9,000) and $211,000, respectively, compared to a tax expense of $124,000 and (benefit) of ($42,000), respectively, for the three and nine months ended June 30, 2012. The effective tax rates for the three months ended June 30, 2013 and 2012 were (3%) and 32%, respectively. The effective tax benefit rate for the three months ended June 30, 2013 differs from the statutory rate, primarily because of the favorable impact of the Federal Research and Development Tax Credit (“Federal R&D Tax Credit”) forecast for the fiscal year, and the impact of the cumulative adjustment resulting from a revised forecast annual effective tax rate. On January 1, 2013, Congress enacted the American Taxpayer Relief Act of 2012 which retroactively reinstated and extended the Federal R&D Tax Credit from January 1, 2012 to December 31, 2013. The current year estimated annual effective income tax rate reflects a full year benefit from the Federal R&D Tax Credit. The effective tax rate for the three months ended June 30, 2012 differs from the statutory rate primarily because of the net benefits of R&D tax credits utilized, which did not generate deferred tax expense in that period because of the federal valuation allowance that the Company maintained at that time. The effective tax rate for the nine months ended June 30, 2013 was 11%. The effective tax rate differs from the statutory rate for the nine months ended June 30, 2013 primarily because of the favorable impact of the extension of the Federal R&D Tax Credit mentioned above. The retroactive benefit for the previously expired period from January 1, 2012 to September 2012 is reflected in the tax expense for the nine months ended June 30, 2013. The effective tax benefit rate for the nine months ended June 30, 2012 was (26%). The effective tax benefit rate differs from the statutory rate for the nine months ended June 30, 2012 primarily because of a decrease in the liability recorded for uncertain tax positions due to the lapse of an applicable statute of limitation and utilization of R&D tax credits. At September 30, 2012, the Company considered all available evidence, including the recent history of income before income taxes, together with projections of profitability in future periods and, as a result of this analysis, determined that the positive evidence was sufficient to conclude that it was appropriate to reverse the valuation allowance previously recorded against its net federal deferred tax assets. At June 30, 2013, the balance of the deferred tax valuation allowance relates principally to NOL of certain state taxing jurisdictions. The Company will continue to maintain the balance of the valuation allowance until an appropriate level of profitability is sustained in certain jurisdictions to warrant a conclusion that it is no longer more likely than not that a portion, or all, of these net state deferred tax assets will not be realized in future periods. The Company believes that its estimate of future taxable income is inherently uncertain, and if its current or future operations generate losses, further adjustments to the valuation allowance are possible.

3. Income Taxes

At the end of each interim reporting period, the Company prepares an estimate of the annual effective income tax rate, which is applied to year-to-date income to compute income tax expense exclusive of discrete items. Tax items discrete to a specific quarter are included in computing the income tax expense for that quarter. The estimated annual effective tax rate used in providing for income taxes on a year-to-date basis may change in subsequent interim periods.

The income tax (benefit) expense for the three and nine months ended June 30, 2013 was ($9,000) and $211,000, respectively, compared to a tax expense of $124,000 and (benefit) of ($42,000), respectively, for the three and nine months ended June 30, 2012.

The effective tax rates for the three months ended June 30, 2013 and 2012 were (3%) and 32%, respectively. The effective tax benefit rate for the three months ended June 30, 2013 differs from the statutory rate, primarily because of the favorable impact of the Federal Research and Development Tax Credit (“Federal R&D Tax Credit”) forecast for the fiscal year, and the impact of the cumulative adjustment resulting from a revised forecast annual effective tax rate. On January 1, 2013, Congress enacted the American Taxpayer Relief Act of 2012 which retroactively reinstated and extended the Federal R&D Tax Credit from January 1, 2012 to December 31, 2013. The current year estimated annual effective income tax rate reflects a full year benefit from the Federal R&D Tax Credit. The effective tax rate for the three months ended June 30, 2012 differs from the statutory rate primarily because of the net benefits of R&D tax credits utilized, which did not generate deferred tax expense in that period because of the federal valuation allowance that the Company maintained at that time.

The effective tax rate for the nine months ended June 30, 2013 was 11%. The effective tax rate differs from the statutory rate for the nine months ended June 30, 2013 primarily because of the favorable impact of the extension of the Federal R&D Tax Credit mentioned above. The retroactive benefit for the previously expired period from January 1, 2012 to September 2012 is reflected in the tax expense for the nine months ended June 30, 2013. The effective tax benefit rate for the nine months ended June 30, 2012 was (26%). The effective tax benefit rate differs from the statutory rate for the nine months ended June 30, 2012 primarily because of a decrease in the liability recorded for uncertain tax positions due to the lapse of an applicable statute of limitation and utilization of R&D tax credits.

At September 30, 2012, the Company considered all available evidence, including the recent history of income before income taxes, together with projections of profitability in future periods and, as a result of this analysis, determined that the positive evidence was sufficient to conclude that it was appropriate to reverse the valuation allowance previously recorded against its net federal deferred tax assets. At June 30, 2013, the balance of the deferred tax valuation allowance relates principally to NOL of certain state taxing jurisdictions. The Company will continue to maintain the balance of the valuation allowance until an appropriate level of profitability is sustained in certain jurisdictions to warrant a conclusion that it is no longer more likely than not that a portion, or all, of these net state deferred tax assets will not be realized in future periods. The Company believes that its estimate of future taxable income is inherently uncertain, and if its current or future operations generate losses, further adjustments to the valuation allowance are possible.